Royalty PharmaRPRX
RPRX
About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Employees: 99
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
160% more call options, than puts
Call options by funds: $89M | Put options by funds: $34.2M
68% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 50
16% more capital invested
Capital invested by funds: $8.18B [Q4 2024] → $9.48B (+$1.3B) [Q1 2025]
7% more funds holding
Funds holding: 411 [Q4 2024] → 439 (+28) [Q1 2025]
8% more repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 145
1.89% less ownership
Funds ownership: 72.13% [Q4 2024] → 70.24% (-1.89%) [Q1 2025]
22% less funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 7 (-2) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for RPRX.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.
Neutral
GlobeNewsWire
4 weeks ago
Royalty Pharma Completes the Acquisition of Its External Manager
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction.
Neutral
GlobeNewsWire
1 month ago
Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
Neutral
GlobeNewsWire
1 month ago
Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma's 2025 Annual General Meeting and Special Meeting of Shareholders (the “Meeting”), marking a key milestone for the company.
Positive
Seeking Alpha
1 month ago
Royalty Pharma: Again, Guidance Raised, Buy Confirmed
Royalty Pharma reported 12% growth in Q1 royalty receipts, driven by Vertex, GSK, and Roche, with adjusted EBITDA reaching $738 million. The company raised its 2025 Portfolio Receipts guidance to $2.97-$3.12 billion, suggesting potential growth opportunities not yet reflected in the current valuation. RPRX repurchased 23 million shares for $723 million and has a $2.3 billion buyback remaining, with a 2.6% dividend yield.
Neutral
Seeking Alpha
1 month ago
Royalty Pharma plc (RPRX) Q1 2025 Earnings Call Transcript
Royalty Pharma plc (NASDAQ:RPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants George Grofik - Senior Vice President and Head, Investor Relations and Communications Pablo Legorreta - Founder and CEO Marshall Urist - Executive Vice President and Head, Research and Investment Terry Coyne - Executive Vice President and CFO Chris Hite - Executive Vice President and Vice Chairman Conference Call Participants Hardik Parikh - JPMorgan Mike Nedelcovych - TD Cowen Terence Flynn - Morgan Stanley Geoff Meacham - Citi Jason Gerberry - Bank of America Securities Operator Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma First Quarter Earnings Conference Call.
Neutral
Zacks Investment Research
1 month ago
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Positive
Zacks Investment Research
1 month ago
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.98 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Royalty Pharma Reports First Quarter 2025 Results
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.
Positive
Zacks Investment Research
1 month ago
Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Royalty Pharma (RPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Charts implemented using Lightweight Charts™